Insmed (INSM)
(Delayed Data from NSDQ)
$189.60 USD
-4.62 (-2.38%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $189.73 +0.13 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INSM 189.60 -4.62(-2.38%)
Will INSM be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for INSM based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for INSM
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates
INSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for
Other News for INSM
Insmed price target raised to $214 from $139 at Truist
Insmed price target raised by $75 at Truist, here's why
Is INSM signaling a buying opportunity? New 52 Week High shows up after slipping 2.38%
INSM: UBS Maintains 'Buy', Raises Price Target to $223 | INSM Stock News
Insmed (INSM) Sees Price Target Raised by RBC Capital to $215 | INSM Stock News